DRUGS & SUPPLEMENTS
How is the drug helping you?
Melzap is an antiepileptic drugs from the group of benzodiazepine derivatives. This medication has a pronounced anticonvulsant and central muscle relaxant, anxiolytic, sedative and hypnotic effects.
Melzap strengthens the inhibitory effect of GABA on the transmission of nerve impulses.
Anxiolytic effects of this drug is due to the influence on the amygdaloid complex of the limbic system and appears in reducing the emotional stress, reduce anxiety, fear, anxiety.
The sedation effects is due to the influence on the reticular formation of the brainstem and nonspecific thalamic nucleus and manifests a decrease in neurotic symptoms.
Anticonvulsant effect is realized by increasing presynaptic inhibition.
The central muscle relaxant effect is due to inhibition of spinal polysynaptic afferent inhibitory ways (to a lesser extent and monosynaptic).
It is possibly and direct inhibition of motor nerves and muscle function.
For oral administration of Melzap its bioavailability is more than 90%. The plasma protein binding is more than 80%. Vd is 3.2 L / kg. T1/2 is 23 hours. This drug is excreted mainly as metabolites.
As the medication of I row - epilepsy : typical absence seizures (petit mal), atypical absence seizures (Lennox-Gastaut syndrome), nodding spasm, atonic seizures (a syndrome of "falling" or "drop-attacks").
As the medication of II row - infantile spasms (West syndrome).
As the medication of III row - tonic-clonic seizures (grand mal), simple and complex partial seizures and secondary generalized tonic-clonic seizures.
Status epilepticus (IV injections).
Somnambulism, muscular hypertonicity, insomnia (especially in patients with organic brain damage), psychomotor agitation, alcohol withdrawal syndrome (acute agitation, tremor, threatening or acute delirium tremens and hallucinations), panic disorder.
Dosing regimen of Melzap is individual. For oral administration for adults the recommended initial dose is not more than 1 mg / day. The maintenance dose is 4-8 mg / day.
For infants and children aged 1-5 years, the initial dose should not exceed 250 micrograms / day, for children aged 5-12 years - 500 mcg / day. Supporting daily doses for children under 1 year are 0.5-1 mg, 1-5 years - 1-3 mg, 5-12 years - 3-6 mg.
For elderly patients the recommended starting dose is not exceeding 500 micrograms.
The daily dose should be divided into 3-4 equal doses. Maintenance doses prescribed in 2-3 weeks of treatment.
IV (slowly) for adults - 1 mg, for children under the age of 12 years - 500 mcg.
CNS: early treatment - severe lethargy, fatigue, drowsiness, weakness, dizziness, stupor, headache; rarely - confusion, ataxia. When used in high doses, especially in long-term treatment - violation of articulation, diplopia, nystagmus, paradoxical reactions ; anterograde amnesia. Rarely - hyperergic reactions, muscle weakness - depression. With long-term treatment of some forms of epilepsy may increase the frequency of seizures.
Digestive system: rarely - dry mouth, nausea, diarrhea, heartburn, nausea, vomiting, decreased appetite, constipation or diarrhea, liver damage, elevated liver transaminases and alkaline phosphatase, jaundice. In infants and young children may increase salivation.
Cardiovascular system: decreased blood pressure, tachycardia.
Endocrine: changes in libido, dysmenorrhea, reversible premature sexual development in children (part-time early puberty).
Respiratory system: with / in the introduction possible respiratory depression, particularly after treatment with other medicines that cause respiratory depression; in infants and young children it is possible bronchial hypersecretion.
Hematopoietic system: leukopenia, neutropenia, agranulocytosis, anemia, and thrombocytopenia.
Urinary system: urinary incontinence, urinary retention, impaired renal function.
Allergic reactions: hives, skin rash, itching, extremely rare - anaphylactic shock.
Dermatological reactions: transient alopecia, discoloration.
Other: addiction, drug dependence, with a sharp decrease in dose or cessation of reception - a withdrawal syndrome.
Inhibition of the respiratory center, severe COPD (the progression of the degree of respiratory failure), acute respiratory failure, myasthenia gravis, coma, shock, angle-closure glaucoma (acute attack or predisposition), acute alcohol intoxication with the weakening of the vital functions, acute poisoning with narcotic analgesics and hypnotics, severe depression (suicidal tendencies may occur), pregnancy, lactation, hypersensitivity to Melzap.
Melzap is contraindicated for use during pregnancy and lactation. This medication crosses the placental barrier. Melzap may be excreted in breast milk.
Category effects on the fetus by FDA - D.
With caution used in patients with ataxia, severe liver disease, severe chronic respiratory failure, especially in the acute stage of deterioration, with episodes of sleep apnea.
With careful use in elderly patients because they may be slowed by removal of Melzap and reduced tolerance, especially in the presence of cardio-pulmonary insufficiency.
With prolonged use of this drug it may develop drug dependence. With a sharp lifting of Melzap after long-term treatment it may been developed the withdrawal syndrome.
In long-term use of Melzap in children should be kept in mind the possibility of side effects on physical and mental development, which may not manifest for years.
During the period of treatment avoid to drink alcohol.
During the period of treatment is observed slowing of psychomotor responses. It is necessary to take into account persons engaged in potentially hazardous activities that require attention and quickness of psychomotor reactions.
Simultaneous administration of Melzap with:
Symptoms: CNS depression of varying severity (from lethargy to coma): severe drowsiness, prolonged confusion, depression of reflexes, coma, possible respiratory depression.
Treatment: induction of vomiting and the prescription of activated charcoal (if the patient is conscious), gastric lavage through a tube (if patient is unconscious), symptomatic therapy, monitoring of vital functions (breathing, pulse, blood pressure), in intravenous fluids (to increase urine output), if necessary, mechanical ventilation. As a specific antidote may be used benzodiazepine receptor antagonist flumazenil (in hospital), however, flumazenil is not indicated for use in patients with epilepsy (likely provocation of epileptic seizures).
Depending on the reaction of the Melzap after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Melzap not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Melzap addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology